-
Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Barry Greenberg,Matthew Taylor,Eric Adler,Steven Colan,David Ricks,Paul Yarabe,Pavan Battiprolu,Gaurav Shah,Kinnari Patel,Matthew Coggins,Susanna Carou-Keenan,Jonathan D Schwartz,Joseph W Rossano
BACKGROUND Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predominant phenotype is progressive cardiac hypertrophy, cardiac dysfunction, and early death. There are no directed therapies for the disease. METHODS In this phase 1 study, we evaluated the safety and
-
Oral Infigratinib Therapy in Children with Achondroplasia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Ravi Savarirayan,Josep Maria De Bergua,Paul Arundel,Jean Pierre Salles,Vrinda Saraff,Borja Delgado,Antonio Leiva-Gea,Helen McDevitt,Marc Nicolino,Massimiliano Rossi,Maria Salcedo,Valerie Cormier-Daire,Mars Skae,Peter Kannu,John Phillips,Howard Saal,Paul Harmatz,Toby Candler,Dawn Hill,Elena Muslimova,Richard Weng,Yun Bai,Supriya Raj,Julie Hoover-Fong,Melita Irving,Daniela Rogoff
BACKGROUND Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor in development for achondroplasia. METHODS In this phase 2 dose-finding study, we evaluated the safety and efficacy of oral infigratinib in children with achondroplasia
-
NEJM at AHA - Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-18 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
Routine Spironolactone in Acute Myocardial Infarction. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-17 Sanjit S Jolly,Marc-André d'Entremont,Bertram Pitt,Shun Fu Lee,Rajibul Mian,Jessica Tyrwhitt,Sasko Kedev,Gilles Montalescot,Jan H Cornel,Goran Stanković,Raul Moreno,Robert F Storey,Timothy D Henry,Shamir R Mehta,Matthias Bossard,Petr Kala,Ravinay Bhindi,Biljana Zafirovska,P J Devereaux,John Eikelboom,John A Cairns,Madhu K Natarajan,J D Schwalm,Sanjib K Sharma,Wadea Tarhuni,David Conen,Sarah Tawadros
BACKGROUND Mineralocorticoid receptor antagonists have been shown to reduce mortality in patients after myocardial infarction with congestive heart failure. Whether routine use of spironolactone is beneficial after myocardial infarction is uncertain. METHODS In this multicenter trial with a 2-by-2 factorial design, we randomly assigned patients with myocardial infarction who had undergone percutaneous
-
NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-17 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Marianna Fontana,Scott D Solomon,Jessica Kachadourian,Liron Walsh,Ricardo Rocha,David Lebwohl,Derek Smith,Jörg Täubel,Edward J Gane,Björn Pilebro,David Adams,Yousuf Razvi,Joy Olbertz,Alexandra Haagensen,Peijuan Zhu,Yuanxin Xu,Adia Leung,Alison Sonderfan,David E Gutstein,Julian D Gillmore
BACKGROUND Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Nexiguran ziclumeran (nex-z) is an investigational therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) targeting the gene encoding transthyretin (TTR). METHODS In this phase 1, open-label trial, we administered a single intravenous
-
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Yufang Bi,Mian Li,Yan Liu,Tingzhi Li,Jieli Lu,Peng Duan,Fengmei Xu,Qijuan Dong,Ailiang Wang,Tiange Wang,Ruizhi Zheng,Yuhong Chen,Min Xu,Xiaohu Wang,Xinhuan Zhang,Yanbo Niu,Zhiqiang Kang,Chunru Lu,Jing Wang,Xinwen Qiu,An Wang,Shujing Wu,Jingya Niu,Jingya Wang,Zhiyun Zhao,Huanfeng Pan,Xiaohua Yang,Xiaohong Niu,Shuguang Pang,Xiaoliang Zhang,Yuancheng Dai,Qin Wan,Shihong Chen,Qidong Zheng,Shaoping Dai
BACKGROUND Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear. METHODS We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood pressure, and an increased risk of cardiovascular disease at 145 clinical sites across China. Patients were randomly assigned to receive intensive treatment that targeted a systolic blood pressure
-
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Milton Packer,Michael R Zile,Christopher M Kramer,Seth J Baum,Sheldon E Litwin,Venu Menon,Junbo Ge,Govinda J Weerakkody,Yang Ou,Mathijs C Bunck,Karla C Hurt,Masahiro Murakami,Barry A Borlaug,
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial
-
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Oussama M Wazni,Walid I Saliba,Devi G Nair,Eloi Marijon,Boris Schmidt,Troy Hounshell,Henning Ebelt,Carsten Skurk,Saumil Oza,Chinmay Patel,Arvindh Kanagasundram,Ashish Sadhu,Sri Sundaram,Jose Osorio,George Mark,Madhukar Gupta,David B DeLurgio,Jeffrey Olson,Jens Erik Nielsen-Kudsk,Lucas V A Boersma,Jeff S Healey,Karen P Phillips,Federico M Asch,Katherine Wolski,Kristine Roy,Thomas Christen,Brad S Sutton
BACKGROUND Oral anticoagulation is recommended after ablation for atrial fibrillation among patients at high risk for stroke. Left atrial appendage closure is a mechanical alternative to anticoagulation, but data regarding its use after atrial fibrillation ablation are lacking. METHODS We conducted an international randomized trial involving 1600 patients with atrial fibrillation who had an elevated
-
Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 John L Sapp,Anthony S L Tang,Ratika Parkash,William G Stevenson,Jeff S Healey,Lorne J Gula,Girish M Nair,Vidal Essebag,Lena Rivard,Jean-Francois Roux,Pablo B Nery,Jean-Francois Sarrazin,Guy Amit,Jean-Marc Raymond,Marc Deyell,Chris Lane,Frederic Sacher,Christian de Chillou,Vikas Kuriachan,Amir AbdelWahab,Isabelle Nault,Katia Dyrda,Stephen Wilton,Umjeet Jolly,Arvindh Kanagasundram,George A Wells,
BACKGROUND Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain. METHODS In an international trial
-
Mind the Sentinel - Applying Patient-Safety Paradigms to Clinician Well-Being. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Catherine A Humikowski
-
Saint Didacus, Fetal Death, and the Problem of Dual Loyalty. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Natalie Posever
-
Invisible Deaths - Mortality among People Experiencing Homelessness. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Katherine A Koh
-
NEJM at AHA - CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
NEJM at AHA - Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
NEJM at AHA - Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
NEJM at AHA - Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-16 Eric J Rubin,Jane Leopold,Stephen Morrissey
-
Inebilizumab for Treatment of IgG4-Related Disease. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 John H Stone,Arezou Khosroshahi,Wen Zhang,Emanuel Della Torre,Kazuichi Okazaki,Yoshiya Tanaka,J Matthias Löhr,Nicolas Schleinitz,Lingli Dong,Hisanori Umehara,Marco Lanzillotta,Zachary S Wallace,Mikael Ebbo,George J Webster,Fernando Martinez Valle,Manu K Nayar,Cory A Perugino,Vinciane Rebours,Xinxin Dong,Yanping Wu,Qing Li,Nishi Rampal,Daniel Cimbora,Emma L Culver,
BACKGROUND IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for treating patients with IgG4-related disease. METHODS In this phase 3, multicenter, double-blind, randomized, placebo-controlled trial, adults with active IgG4-related disease underwent randomization
-
Lessons from England's National Health Service. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 Timothy G Ferris,Jennifer Dixon,David Blumenthal
-
Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 Qian Wang,Yicheng Guo,Jerren Ho,David D Ho
-
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 Pete Schmidt,Yong Li,Myra Popejoy
-
Toward Curing More Patients with Bladder Cancer - A New Perioperative Strategy. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 Matthew I Milowsky
-
Transcatheter Repair or Surgery for Functional Mitral Regurgitation. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 Joanna Chikwe,Michelle M Kittleson
-
Case 35-2024: A Newborn with Hypoxemia and a Lung Opacity. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-14 T Bernard Kinane,Evan J Zucker,Katherine A Sparger,Cassandra M Kelleher,Angela R Shih
-
Tirzepatide for Obesity Treatment and Diabetes Prevention. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-13 Ania M Jastreboff,Carel W le Roux,Adam Stefanski,Louis J Aronne,Bruno Halpern,Sean Wharton,John P H Wilding,Leigh Perreault,Shuyu Zhang,Ramakrishna Battula,Mathijs C Bunck,Nadia N Ahmad,Irina Jouravskaya,
BACKGROUND Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying
-
Designing a Legacy — Portraiture as a Tool for Disrupting Structural Sexism and Racism N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 Pamela Chen, and Nancy D. SpectorFrom the Department of Pediatrics, Boston Children’s Hospital, Boston (P.C.), and the Department of Pediatrics and the Executive Leadership in Academic Medicine Program, Drexel University College of Medicine, Philadelphia (N.D.S.).
A gallery of portraits of prominent alumnae of color at Harvard Medical School provides inspiration for diverse current students and makes past sexist practices visible to all.
-
Extensive Tinea Corporis and Tinea Cruris from Trichophyton indotineae. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 Ziyang Xu,Avrom S Caplan
-
Health Equity Rounds - Root-Cause and Solutions-Oriented Discussions of Medical Racism. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 Katherine A Nash,Joanna Perdomo,Heather E Hsu
-
Forensic Nurse Examiners - Meeting the Needs of Survivors of Violent Crimes. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 McKenna C Noe,Miriam Crandall,Caroline Tougas
-
The Menstrual Health Equity Initiative - Access to Menstrual Products for People Experiencing Homelessness. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 Sarah Revak,Karen Cuttin,Bianca Nfonoyim Bernhard,Shelby H Davies
-
Integrating Community Health Workers in Rhode Island - A Roadmap toward Health Equity. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-09 Somava Saha,Geraldine McPhee,Swanette Salazar,Deborah Garneau
-
Simple Strategies to Reduce Cardiac Strain in Older Adults in Extreme Heat N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 Georgia K Chaseling,Nicole T Vargas,Lily Hospers,Hadiatou Barry,Amy Harwood,Connor Graham,Audrey-Ann Bartlett,Amélie Debray,Grant Lynch,Anthony Capon,Craig G Crandall,Maria Fiatarone Singh,Yorgi Mavros,Peng Bi,Anil Nigam,Malorie Chabot-Blanchet,Daniel Gagnon,Ollie Jay
In this crossover trial in older adults with or without coronary artery disease, cardiac strain was reduced with fan use, skin wetting, or both in hot and humid conditions but worsened with fan use in very hot and dry conditions.
-
Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 Vlado Perkovic,Katherine R Tuttle,Richard Pratley
-
SENIOR-RITA - Is It All about Angiography? N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 Simone Biscaglia
-
Audio Interview: The Marburg Virus Outbreak in Rwanda. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 Eric J Rubin,Lindsey R Baden,Sabin Nsanzimana,Stephen Morrissey
-
Epidural Glucocorticoid Injection for Lumbosacral Radicular Pain. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 David Hao,R Jason Yong,Samer Narouze,Alexandra E Fogarty,Olivia M Sutton,Milan P Stojanovic
-
Randomized Trial of Very Early Medication Abortion. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-07 Karin Brandell,Tagrid Jar-Allah,John Reynolds-Wright,Helena Kopp Kallner,Helena Hognert,Frida Gyllenberg,Janina Kaislasuo,Anand Tamang,Heera Tuladhar,Clare Boerma,Karen Schimanski,Gillian Gibson,Mette Løkeland,Pia Teleman,Marie Bixo,Mette Mandrup Kjaer,Ervin Kallfa,Johan Bring,Oskari Heikinheimo,Sharon Cameron,Kristina Gemzell-Danielsson,
BACKGROUND Medication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a pregnancy can be visualized with ultrasonography. METHODS We conducted a multicenter, noninferiority, randomized, controlled trial involving women requesting medication abortion at up to 42
-
Screened Out - How a Survey Change Sheds Light on Iatrogenic Opioid Use Disorder. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-06 Andrew Kolodny,Robert M Bohler
-
I Am Nothing N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-02 Hemal N. SampatFrom the Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston.
When an older patient hears that his physician is of Indian descent, the two find an immediate, resonant connection in a haunting song recalled from long ago and far away.
-
Reframing Cerebral Palsy as a Lifelong Physical Disability. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-11-02 Mark D Peterson
-
Covering Long-Term Care at Home? Implications of a New Proposal for Expanding Medicare N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-30 Madeline R. Sterling, and David C. GrabowskiFrom the Department of Medicine, Weill Cornell Medicine, New York (M.R.S.), and the Department of Health Care Policy, Harvard Medical School, Boston (D.C.G.).
Kamala Harris’s proposal for expanding Medicare to cover long-term care at home is a hopeful sign for millions of Americans, though key questions remain about eligibility, coverage, payments, and f...
-
Early-Stage Results with Transcatheter Tricuspid-Valve Replacement N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-30 Patrick T. O’GaraFrom the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston.
The past two decades have witnessed a renaissance in the evaluation and treatment of patients with valvular heart disease, catalyzed by advances in surgical innovation, transcatheter techniques, an...
-
A Case of Vertical Transmission of Oropouche Virus in Brazil N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-30 Carlos Garcia FilhoSecretaria da Saúde do Estado do Ceará, Fortaleza, BrazilAntônio Silva Lima NetoUniversidade de Fortaleza, Fortaleza, BrazilAna Maria Peixoto Cabral Maia, Luiz Osvaldo Rodrigues da Silva, and Robson da Costa CavalcanteSecretaria da Saúde do Estado do Ceará, Fortaleza, BrazilHigor da Silva MonteiroUniversidade Federal do Ceará, Fortaleza, BrazilKamilla Carneiro Alves Marques, and
In a woman who had Oropouche virus infection in the third trimester of pregnancy followed by stillbirth, phylogenomic results confirmed the link between this stillbirth and the ongoing OROV outbrea...
-
Transcatheter Valve Replacement in Severe Tricuspid Regurgitation N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-30 Rebecca T. Hahn, Raj Makkar, Vinod H. Thourani, Moody Makar, Rahul P. Sharma, Christiane Haeffele, Charles J. Davidson, Akhil Narang, Brian O’Neill, James Lee, Pradeep Yadav, Firas Zahr, Scott Chadderdon, Mackram Eleid, Sorin Pislaru, Robert Smith, Molly Szerlip, Brian Whisenant, Nishant K. Sekaran, Santiago Garcia, Terri Stewart-Dehner, Holger Thiele, Robert Kipperman, Konstantinos Koulogiannis, D
Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed....
-
Watchful Waiting versus Antibiotics for Acute Otitis Media in Pediatric Patients N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Julie R. Barzilay, Mary Anne Jackson, and David Tunkel
This case vignette of a 13-month-old girl with fever and acute otitis media in one ear is accompanied by two essays, one recommending watchful waiting with close follow-up and the other supporting ...
-
Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Richard C. Cabot, Eric S. Rosenberg, David M. Dudzinski, Meridale V. Baggett, Kathy M. Tran, Dennis C. Sgroi, Jo-Anne O. Shepard, Emily K. McDonald, and Tara CorpuzKevin Heaton, Emily K. Zern, Aferdita Spahillari, and Conor D. BarrettFrom the Department of Medicine, Massachusetts General Hospital (K.H., E.K.Z., A.S., C.D.B.), and the Department of Medicine, Harvard Medical School (K.H., E.K.Z., A.S
A 69-year-old man with a history of MI and cardiomyopathy presented with 2 days of dyspnea. Regular tachycardia (124 beats per min), diaphoresis, and rales were present. A diagnosis was made.
-
Erysipelas N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Nathan I. Wood, and Andre N. SofairYale School of Medicine, New Haven, CT
A 44-year-old man with infliximab-treated Crohn’s disease presented with a 2-day history of rash on his face. Well-demarcated, warm, erythematous, confluent plaques were seen across the cheeks, nos...
-
Improving the Outcome of Bad-Acting Hormone Receptor–Positive Breast Cancer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 William J. GradisharFrom the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago.
The treatment approach for patients with estrogen receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer has changed dramatically over the past 20 year...
-
Glucagon-Like Peptide-1 Receptor Agonists and Osteoarthritis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 David T. FelsonFrom the Boston University School of Medicine, Boston, MA.
Osteoarthritis is one of the world’s leading causes of disability. Roughly 4.3% of adults have painful knee osteoarthritis, with knee pain on most days1; the prevalence of disease is much higher th...
-
Ten-Year Outcomes after Bariatric Surgery in Adolescents N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Justin R. RyderAnn and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL odd M. Jenkins, and Changchun XieUniversity of Cincinnati, College of Medicine, Cincinnati, OHAnita P. CourcoulasUniversity of Pittsburgh Medical Center, Pittsburgh, PACarroll M. HarmonJohn R. Oishei Children’s Hospital, Buffalo, NYMichael A. HelmrathCincinnati Children’s Hospital Medical Center, Cincinnati, OHStephanie
A study documents the long-term durability of weight loss and remission of related conditions after bariatric surgery, as well as the greater health benefits in adolescents than would be expected i...
-
HIV-Associated Tuberculosis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31
To the Editor: In their review of human immunodeficiency virus (HIV)–associated tuberculosis, Meintjes and Maartens (July 25 issue)1 highlight the excess mortality from tuberculosis among patients ...
-
More on Type 2 Diabetes in Patients with G6PD Deficiency N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31
To the Editor: The study by Israel et al. (Aug. 8 issue),1 as reported in the Correspondence section, showed glycated hemoglobin levels that markedly underestimated glucose levels in patients with ...
-
Postacute Sequelae of SARS-CoV-2 Infection in Several Eras N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31
To the Editor: In the article by Xie et al. (Aug. 8 issue)1 regarding postacute sequelae of SARS-CoV-2 infection (PASC) in the pre-delta, delta, and omicron eras, the authors note that 71.89% of th...
-
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31
To the Editor: The report by Quiroz et al. (June 20 issue)1 on the Colombian PSEN1E280A pedigree suggests a protective effect of apolipoprotein E3 Christchurch (APOE3Ch) variant heterozygosity. The...
-
Lead Poisoning N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Bruce Lanphear, Ana Navas-Acien, and David C. Bellinger
Chronic lead poisoning, even at low levels, is a risk factor for cardiovascular disease in adults and cognitive deficits in children. The authors review the effects of chronic, low-level lead poisoning.
-
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, and Komal L. JhaveriFrom the Royal Marsden Hospital
Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degr...
-
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Henning Bliddal, Harold Bays, Sébastien Czernichow, Joanna Uddén Hemmingsson, Jøran Hjelmesæth, Thomas Hoffmann Morville, Anna Koroleva, Jesper Skov Neergaard, Patricia Vélez Sánchez, Sean Wharton, Alicja Wizert, and Lars E. Kristensenthe STEP 9 Study Group*From the Parker Institute, Copenhagen University Hospital at Bispebjerg and Frederiksberg, Copenhagen (H. Bliddal, L.E.K.), and Novo Nordisk, Søborg
Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among...
-
A Randomized Trial of Drug Route in Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Keith Couper,Chen Ji,Charles D Deakin,Rachael T Fothergill,Jerry P Nolan,John B Long,James M Mason,Felix Michelet,Chloe Norman,Henry Nwankwo,Tom Quinn,Anne-Marie Slowther,Michael A Smyth,Kath R Starr,Alison Walker,Sara Wood,Steve Bell,Gemma Bradley,Martina Brown,Shona Brown,Emma Burrow,Karl Charlton,Andrew Claxton Dip,Victoria Dra'gon,Christine Evans,Jakob Falloon,Theresa Foster,Justin Kearney,Nigel
BACKGROUND In patients with out-of-hospital cardiac arrest, the effectiveness of drugs such as epinephrine is highly time-dependent. An intraosseous route of drug administration may enable more rapid drug administration than an intravenous route; however, its effect on clinical outcomes is uncertain. METHODS We conducted a multicenter, open-label, randomized trial across 11 emergency medical systems
-
Intraosseous or Intravenous Vascular Access for Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. (IF 96.2) Pub Date : 2024-10-31 Mikael F Vallentin,Asger Granfeldt,Thomas L Klitgaard,Søren Mikkelsen,Fredrik Folke,Helle C Christensen,Amalie L Povlsen,Alberthe H Petersen,Sofie Winther,Lea W Frilund,Carsten Meilandt,Mathias J Holmberg,Kristian B Winther,Allan Bach,Thomas H Dissing,Christian J Terkelsen,Steffen Christensen,Line Kirkegaard Rasmussen,Lone R Mortensen,Mads L Loldrup,Thomas Elkmann,Anders G Nielsen,Charlotte Runge,Elise
BACKGROUND Out-of-hospital cardiac arrest is a leading cause of death worldwide. Establishing vascular access is critical for administering guideline-recommended drugs during cardiopulmonary resuscitation. Both the intraosseous route and the intravenous route are used routinely, but their comparative effectiveness remains unclear. METHODS We conducted a randomized clinical trial to compare the effectiveness